Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Part one of a two-part series on FDA Commissioner Martin Makary, M.D.s comments at the Gailen Forum in New York City on October 30, 2025.

Women leaders are driving success in life sciences but remain underrepresented and undervalued. That needs to change, writes ...

Pay close attention to contract language regarding royalties, including when and where patents expire, or pay the price, ...

Believing “good companies are bought, not sold” does not reflect the reality of most life sciences transactions, write ...

The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

Since clinical trials have become increasingly complex with more data being collected, this consequently puts more pressure on sponsors to improve efficiencies while still maintaining quality.

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

Life Science industry experts from Life Science Leaders editorial advisory board answer your questions ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...